EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Associations of minor histocompatibility antigens with outcomes following allogeneic hematopoietic cell transplantation

Othmane Jadi iD, Hancong Tang, Kelly Olsen, Steven Vensko, Qianqian Zhu, Yiwen Wang, Christopher A Haiman, Loreall Pooler, Xin Sheng, Guy Brock, Amy Webb, Marcelo C Pasquini und 6 weitere

American Journal of Hematology · 2023-06 · 98 (6) · 940-950

DOI: 10.1002/ajh.26925 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 13.04.2023. Verfasst von Othmane Jadi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB# 7295, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, HRSA HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The role of minor histocompatibility antigens (mHAs) in mediating graft versus leukemia and graft versus host disease (GvHD) following allogeneic hematopoietic cell transplantation (alloHCT) is recognized but not well‐characterized. By implementing improved methods for mHA prediction in two large patient cohorts, this study aimed to comprehensively explore the role of mHAs in alloHCT by analyzing whether (1) the number of predicted mHAs, or (2) individual mHAs are associated with clinical outcomes. The study population consisted of 2249 donor–recipient pairs treated for acute myeloid leukemia and myelodysplastic syndrome with alloHCT. A Cox proportional hazard model showed that patients with a class I mHA count greater than the population median had an increased hazard of GvHD mortality (hazard ratio [HR] = 1.39, 95% confidence interval [CI] = 1.01, 1.77, p = .046). Competing risk analyses identified the class I mHAs DLRCKYISL ( GSTP ), WEHGPTSLL ( CRISPLD2 ), and STSPTTNVL ( SERPINF2 ) were associated with increased GVHD mortality (HR = 2.84, 95% CI = 1.52, 5.31, p = .01), decreased leukemia‐free survival (LFS) (HR = 1.94, 95% CI = 1.27, 2.95, p = .044), and increased disease‐related mortality (DRM) (HR = 2.32, 95% CI = 1.5, 3.6, p = .008), respectively. One class II mHA YQEIAAIPSAGRERQ ( TACC2 ) was associated with increased risk of treatment‐related mortality (TRM) (HR = 3.05, 95% CI = 1.75, 5.31, p = .02). WEHGPTSLL and STSPTTNVL were both present within HLA haplotype B*40:01‐C*03:04 and showed a positive dose–response relationship with increased all‐cause mortality and DRM and decreased LFS, indicating these two mHAs contribute to the risk of mortality in an additive manner. Our study reports the first large‐scale investigation of the associations of predicted mHA peptides with clinical outcomes following alloHCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationGraft vs Host DiseaseLeukemia, Myeloid, AcuteHumansMinor Histocompatibility AntigensTransplantation, HomologousRetrospective Studies

Substanzen

Minor Histocompatibility Antigens

Autor:innen und Institutionen

  • Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB# 7295, Chapel Hill, North Carolina, USA.
  • College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
  • Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • Quantitative Sciences Unit, Department of Medicine, Stanford University, Palo Alto, California, USA.
  • Department of Preventive Medicine, University of Southern California, Los Angeles, California, USA.
  • The Center for Genetic Epidemiology, University of Southern California, Los Angeles, California, USA.

ORCID-Profile: Othmane Jadi, Stephen R Spellman

Förderung

  • NCI NIH HHS
  • HRSA HHS
  • NHLBI NIH HHS
  • National Cancer Institute
  • National Heart, Lung, and Blood Institute
  • National Institute of Allergy and Infectious Diseases
  • Health Resources and Services Administration
  • Office of Naval Research

Zitieren

APA

Jadi, O., Tang, H., Olsen, K., Vensko, S., Zhu, Q., Wang, Y., Haiman, C. A., Pooler, L., Sheng, X., Brock, G., Webb, A., Pasquini, M. C., McCarthy, P. L., Spellman, S. R., Hahn, T., Vincent, B., Armistead, P., & Sucheston-Campbell, L. E. (2023). Associations of minor histocompatibility antigens with outcomes following allogeneic hematopoietic cell transplantation. American Journal of Hematology, 98(6), 940-950. https://doi.org/10.1002/ajh.26925

Vancouver

Jadi O, Tang H, Olsen K, Vensko S, Zhu Q, Wang Y, et al. Associations of minor histocompatibility antigens with outcomes following allogeneic hematopoietic cell transplantation. American Journal of Hematology. 2023;98(6):940-950. doi:10.1002/ajh.26925

BibTeX
@article{Jadi2023,
  author = {Jadi, Othmane and Tang, Hancong and Olsen, Kelly and Vensko, Steven and Zhu, Qianqian and Wang, Yiwen and Haiman, Christopher A and Pooler, Loreall and Sheng, Xin and Brock, Guy and Webb, Amy and Pasquini, Marcelo C and McCarthy, Philip L and Spellman, Stephen R and Hahn, Theresa and Vincent, Benjamin and Armistead, Paul and Sucheston-Campbell, Lara E},
  title = {Associations of minor histocompatibility antigens with outcomes following allogeneic hematopoietic cell transplantation},
  journal = {American Journal of Hematology},
  year = {2023},
  volume = {98},
  number = {6},
  pages = {940--950},
  doi = {10.1002/ajh.26925}
}
Kostenlos starten →